Discovery - University of Dundee - Online Publications

Library & Learning Centre

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

Standard

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. / Ånensen, N.; Hjelle, S. M.; Van Belle, W.; Haaland, I.; Silden, E.; Bourdon, J.-C.; Hovland, R.; Taskén, K.; Knappskog, S.; Lønning, P.E.; Bruserud, O.; Gjertsen, B. T.

In: Oncogene, Vol. 31, No. 12, 2012, p. 1533-1545.

Research output: Contribution to journalArticle

Harvard

Ånensen, N, Hjelle, SM, Van Belle, W, Haaland, I, Silden, E, Bourdon, J-C, Hovland, R, Taskén, K, Knappskog, S, Lønning, PE, Bruserud, O & Gjertsen, BT 2012, 'Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia' Oncogene, vol 31, no. 12, pp. 1533-1545.

APA

Ånensen, N., Hjelle, S. M., Van Belle, W., Haaland, I., Silden, E., Bourdon, J-C., Hovland, R., Taskén, K., Knappskog, S., Lønning, P. E., Bruserud, O., & Gjertsen, B. T. (2012). Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene, 31(12), 1533-1545doi: 10.1038/onc.2011.348

Vancouver

Ånensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon J-C et al. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 2012;31(12):1533-1545.

Author

Ånensen, N.; Hjelle, S. M.; Van Belle, W.; Haaland, I.; Silden, E.; Bourdon, J.-C.; Hovland, R.; Taskén, K.; Knappskog, S.; Lønning, P.E.; Bruserud, O.; Gjertsen, B. T. / Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.

In: Oncogene, Vol. 31, No. 12, 2012, p. 1533-1545.

Research output: Contribution to journalArticle

Bibtex - Download

@article{4dd62a7e037947dc8942a4508ddcb51e,
title = "Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia",
author = "N. Ånensen and Hjelle, {S. M.} and {Van Belle}, W. and I. Haaland and E. Silden and J.-C. Bourdon and R. Hovland and K. Taskén and S. Knappskog and P.E. Lønning and O. Bruserud and Gjertsen, {B. T.}",
note = "MEDLINE® is the source for the MeSH terms of this document.",
year = "2012",
volume = "31",
number = "12",
pages = "1533--1545",
journal = "Oncogene",
issn = "0950-9232",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

A1 - Ånensen,N.

A1 - Hjelle,S. M.

A1 - Van Belle,W.

A1 - Haaland,I.

A1 - Silden,E.

A1 - Bourdon,J.-C.

A1 - Hovland,R.

A1 - Taskén,K.

A1 - Knappskog,S.

A1 - Lønning,P.E.

A1 - Bruserud,O.

A1 - Gjertsen,B. T.

AU - Ånensen,N.

AU - Hjelle,S. M.

AU - Van Belle,W.

AU - Haaland,I.

AU - Silden,E.

AU - Bourdon,J.-C.

AU - Hovland,R.

AU - Taskén,K.

AU - Knappskog,S.

AU - Lønning,P.E.

AU - Bruserud,O.

AU - Gjertsen,B. T.

PY - 2012

Y1 - 2012

N2 - The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms ? and ? expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. © 2012 Macmillan Publishers Limited All rights reserved.

AB - The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms ? and ? expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. © 2012 Macmillan Publishers Limited All rights reserved.

U2 - 10.1038/onc.2011.348

DO - 10.1038/onc.2011.348

M1 - Article

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 12

VL - 31

SP - 1533

EP - 1545

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy